Treatment of osteoporosis in children with glucocorticoid-treated diseases

References

• Iqbal J, Sun L, Zaidi M. Commentary-FSH and bone 2010: evolving evidence. Eur J Endocrinol 2010;163(1):173-6
   Google Scholar
• Cannon JG, Kraj B, Sloan G. Follicle-stimulating hormone promotes RANK expression on human monocytes. Cytokine 2011;53(2):141-4
   Google Scholar
• Faienza MF, Ventura A, Marzano F, Cavallo L. Postmenopausal osteoporosis: the role of immune system cells. Clin Dev Immunol 2013;2013:575936
   Google Scholar
• Leonard MB, Zemel BS. Current concepts in pediatric bone disease. Pediatr Clin North Am 2002;49(1):143-73
   Google Scholar
• Greer FR, Krebs NF; American Academy of Pediatrics Committee on Nutrition. Optimizing bone health and calcium intakes of infants, children, and adolescents. Pediatrics 2006;117(2):578-85
   PubMed Web of Science ®Google Scholar
• Bianchi ML, Leonard MB, Bechtold S, et al. Bone health in children and adolescents with chronic diseases that may affect the skeleton: the 2013 ISCD pediatric official positions. J Clin Densitom 2014;17(2):281-94
   Web of Science ®Google Scholar
• Crabtree NJ, Arabi A, Bachrach LK, et al. Dual-energy X-Ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD pediatric official positions. J Clin Densitom 2014;17(2):225-42
   PubMed Web of Science ®Google Scholar
• Wren TA, Liu X, Pitukcheewanont P, Gilsanz V. Bone densitometry in pediatric populations: discrepancies in the diagnosis of osteoporosis by DXA and CT. J Pediatr 2005;146(6):776-9
   Google Scholar
• Gafni RI, Baron J. Overdiagnosis of osteoporosis in children due to misinterpretation of dual-energy x-ray absorptiometry (DEXA). J Pediatr 2004;144(2):253-7
   PubMed Web of Science ®Google Scholar
• Baroncelli GI, Federico G, Vignolo M, et al. Cross-sectional reference data for phalangeal quantitative ultrasound from early childhood to young-adulthood according to gender, age, skeletal growth, and pubertal development. Bone 2006;39(1):159-73
   PubMed Web of Science ®Google Scholar
• Engelke K, Libanati C, Liu Y, et al. Quantitative computed tomography (QCT) of the forearm using general purpose spiral whole-body CT scanners: accuracy, precision and comparison with dual-energy X-ray absorptiometry (DXA). Bone 2009;45(1):110-18
   PubMed Web of Science ®Google Scholar
• Krieg MA, Barkmann R, Gonnelli S, et al. Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom 2008;11(1):163-87
   PubMedGoogle Scholar
• Baroncelli GI, Federico G, Bertelloni S, et al. Assessment of bone quality by quantitative ultrasound of proximal phalanges of the hand and fracture rate in children and adolescents with bone and mineral disorders. Pediatr Res 2003;54(1):125-36
   Google Scholar
• Christoforidis A, Printza N, Gkogka C, et al. Comparative study of quantitative ultrasonography and dual-energy X-ray absorptiometry for evaluating renal osteodystrophy in children with chronic kidney disease. J Bone Miner Metab 2011;29(3):321-7
   Google Scholar
• Guglielmi G, de Terlizzi F, Aucella F. Quantitative bone ultrasonography: state of the art and perspectives. G Ital Nefrol 2004;21(4):343-54
   Google Scholar
• Aceto G, D’Addato O, Messina G, et al. Bone health in children and adolescents with Steroid-Sensitive Nephrotic Syndrome assessed by DXA and QUS. Pediatr Nephrol 2014. [Epub ahead of print]
   Google Scholar
• Mazziotti G, Angeli A, Bilezikian JP, et al. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 2006;17(4):144-9
   PubMed Web of Science ®Google Scholar
• Ventura A, Brunetti G, Colucci S, et al. Glucocorticoid-induced osteoporosis in children with 21-hydroxylase deficiency. Biomed Res Int 2013;2013:250462
   Google Scholar
• Ikeda S, Morishita Y, Tsutsumi H, et al. Reductions in bone turnover, mineral, and structure associated with mechanical properties of lumbar vertebra and femur in glucocorticoid-treated growing minipigs. Bone 2003;33(5):779-87
   Google Scholar
• White PC, Bachega TA. Congenital adrenal hyperplasia due to 21 hydroxylase deficiency: from birth to adulthood. Semin Reprod Med 2012;30:400-9
   PubMed Web of Science ®Google Scholar
• Bachelot A, Chakhtoura Z, Samara-Boustani D, et al. Bone health should be an important concern in the care of patients affected by 21 hydroxylase deficiency. Int J Pediatr Endocrinol 2010;2010: pii: 326275
   Google Scholar
• Delvecchio M, Soldano L, Lonero A, et al. Evaluation of impact of steroid replacement treatment on bone health in children with 21-hydroxylase deficiency. Endocrine 2014;doi:10.1007/s12020-014-0332-9. In press
   Google Scholar
• Faienza MF, Brunetti G, Colucci S, et al. Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin imbalance. J Clin Endocrinol Metab 2009;94(7):2269-76
   PubMed Web of Science ®Google Scholar
• Brunetti G, Faienza MF, Piacente L, et al. High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment. Am J Physiol Endocrinol Metab 2013;304(5):E546-54
   Google Scholar
• Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347(6):417-29
   PubMed Web of Science ®Google Scholar
• van Staa TP, Cooper C, Brusse LS, et al. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003;125(6):1591-7
   Google Scholar
• Burnham JM, Shults J, Semeao E, et al. Body-composition alterations consistent with cachexia in children and young adults with Crohn disease. Am J Clin Nutr 2005;82(2):413-20
   PubMed Web of Science ®Google Scholar
• Niaudet P. Long-term outcome of children with steroid-sensitive idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 2009;4(10):1547-8
   Google Scholar
• Leonard MB, Feldman HI, Shults J, et al. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 2004;351(9):868-75
   Google Scholar
• Wetzsteon RJ, Shults J, Zemel BS, et al. Divergent effects of glucocorticoids on cortical and trabecular compartment BMD in childhood nephrotic syndrome. J Bone Miner Res 2009;24(3):503-13
   PubMedGoogle Scholar
• Tsampalieros A, Gupta P, Denburg MR, et al. Glucocorticoid effects on changes in bone mineral density and cortical structure in childhood nephrotic syndrome. J Bone Miner Res 2013;28(3):480-8
   Google Scholar
• Wüster C, Albanese C, De Aloysio D, et al. Phalangeal osteosonogrammetry study (PhOS): age related changes, diagnostic sensitivity and discrimination power. J Bone Miner Res 2000;15:1603-14
   PubMed Web of Science ®Google Scholar
• Knapp KM Quantitative ultrasound and bone health. Salud Publica Mex 2009;51:S18-24
   Google Scholar
• Rizzoli R, Bonjour JP, Ferrari SL. Osteoporosis, genetics and hormones. J Mol Endocrinol 2001;26(2):79-94
   PubMed Web of Science ®Google Scholar
• Alwis G, Linden C, Stenevi-Lundgren S, et al. A school-curriculum-based exercise intervention program for two years in pre-pubertal girls does not influence hip structure. Dyn Med 2008;7:8
   PubMedGoogle Scholar
• Rautava E, Lehtonen-Veromaa M, Kautiainen H, et al. The reduction of physical activity reflects on the bone mass among young females: a follow-up study of 142 adolescent girls. Osteoporos Int 2007;18(7):915-22
   Google Scholar
• Chevalley T, Bonjour JP, Ferrari S, Rizzoli R. High-protein intake enhances the positive impact of physical activity on BMC in prepubertal boys. J Bone Miner Res 2008;23(1):131-42
   Google Scholar
• Winzenberg T, Shaw K, Fryer J, Jones G. Effects of calcium supplementation on bone density in healthy children: meta-analysis of randomised controlled trials. BMJ 2006;333(7572):775
   Google Scholar
• Seiquer I, Mesías M, Hoyos AM, et al. A Mediterranean dietary style improves calcium utilization in healthy male adolescents. J Am Coll Nutr 2008;27(4):454-62
   PubMed Web of Science ®Google Scholar
• Cutolo M. Vitamin D and autoimmune rheumatic diseases. Rheumatology (Oxford) 2009;48(3):210-12
   Google Scholar
• Wagner CL, Greer FR; American Academy of Pediatrics Section on Breastfeeding; American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008;122(5):1142-52
   PubMed Web of Science ®Google Scholar
• Bak M, Serdaroglu E, Guclu R. Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome. Pediatr Nephrol 2006;21(3):350-4
   Google Scholar
• Bowden SA, Robinson RF, Carr R, Mahan JD. Prevalence of vitamin D deficiency and insufficiency in children with osteopenia or osteoporosis referred to a pediatric metabolic bone clinic. Pediatrics 2008;121(6):e1585-90
   Google Scholar
• Maalouf J, Nabulsi M, Vieth R, et al. Short- and long-term safety of weekly high-dose vitamin D3 supplementation in school children. J Clin Endocrinol Metab 2008;93(7):2693-701
   Google Scholar
• Kilpinen-Loisa P, Nenonen H, Pihko H, Mäkitie O. High-dose vitamin D supplementation in children with cerebral palsy or neuromuscular disorder. Neuropediatrics 2007;38(4):167-72
   Google Scholar
• Misra M, Pacaud D, Petryk A, et al. Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008;122(2):398-417
   PubMed Web of Science ®Google Scholar
• El-Hajj Fuleihan G, Nabulsi M, Tamim H, et al. Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. J Clin Endocrinol Metab 2006;91(2):405-12
   Google Scholar
• Russell RG. Bisphosphonates: the first 40 years. Bone 2011;49(1):2-19
   PubMed Web of Science ®Google Scholar
• Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004;363(9418):1377-85
   PubMed Web of Science ®Google Scholar
• Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002;110(9):1293-9
   PubMed Web of Science ®Google Scholar
• Noguera A, Ros JB, Pavía C, et al. Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. J Pediatr Endocrinol Metab 2003;16(4):529-36
   Google Scholar
• Gandrud LM, Cheung JC, Daniels MW, Bachrach LK. Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis. J Pediatr Endocrinol Metab 2003;16(6):887-92
   Google Scholar
• Steelman J, Zeitler P. Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr 2003;142(4):417-23
   PubMed Web of Science ®Google Scholar
• Bachrach LK, Ward LM. Clinical review 1: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009;94(2):400-9
   PubMed Web of Science ®Google Scholar
• Ooi HL, Briody J, Biggin A, et al. Intravenous zoledronic acid given every 6 months in childhood osteoporosis. Horm Res Paediatr 2013;80(3):179-84
   Google Scholar
• Marini JC. Do bisphosphonates make children’s bones better or brittle? N Engl J Med 2003;349(5):423-6
   Google Scholar
• Munns CF, Ooi HL, Briody JN, Cowell CT. Six monthly intravenous zoledronic acid in childhood osteoporosis. Int J Pediatr Endocrinol 2013;2013(Suppl 1):P164
   Google Scholar
• Evans KD, Lau ST, Oberbauer AM, Martin RB. Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. Bone 2003;32(3):268-74
   Google Scholar
• Rauch F, Glorieux FH. Treatment of children with osteogenesis imperfecta. Curr Osteoporos Rep 2006;4:159-64
   PubMedGoogle Scholar
• Unal E, Abaci A, Bober E, Buyukgebiz A. Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis. J Pediatr Endocrinol Metab 2006;19(4):523-8
   Google Scholar
• Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003;111(5 Pt 1):1030-6
   Google Scholar
• Waterhouse KM, Auron A, Srivastava T, et al. Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children. Pediatr Nephrol 2007;22(2):282-77
   Google Scholar
• Lomashvili KA, Monier-Faugere MC, Wang X, et al. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 2009;75(6):617-25
   Google Scholar
• Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2010;95(4):1838-45
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Tsujimoto M, Hamaya E, Sowa H. Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 μg/day administered subcutaneously in Japanese patients with osteoporosis. J Bone Miner Metab 2013;31(2):199-205
   PubMed Web of Science ®Google Scholar
• Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357(20):2028-39
   PubMed Web of Science ®Google Scholar
• Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999;104(4):439-46
   PubMed Web of Science ®Google Scholar
• D’Amelio P, Tamone C, Sassi F, et al. Teriparatide increases the maturation of circulating osteoblast precursors. Osteoporos Int 2012;23(4):1245-53
   Google Scholar
• Watanabe A, Yoneyama S, Nakajima M, et al. Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)). J Toxicol Sci 2012;37(3):617-29
   Google Scholar
• Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 2012;27(12):2429-37
   PubMed Web of Science ®Google Scholar
• Simon D. rhGH treatment in corticosteroid-treated patients. Horm Res 2007;68(1):38-45
   Google Scholar
• Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs 2004;64(7):725-50
   PubMed Web of Science ®Google Scholar
• Gullett NP, Hebbar G, Ziegler TR. Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am J Clin Nutr 2010;91(4):1143S-7S
   PubMed Web of Science ®Google Scholar
• Varness T, Seffrood EE, Connor EL, et al. Oxandrolone improves height velocity and BMI in patients with cystic fibrosis. Int J Pediatr Endocrinol 2009;2009:826895
   Google Scholar
• Danowski TS, Lee FA, Cohn RE, et al. Oxandrolone therapy of growth retardation. Am J Dis Child 1965;109:526-32
   Google Scholar
• Gault EJ, Perry RJ, Cole TJ, et al. Effect of oxandrolone and timing of pubertal induction on final height in Turner’s syndrome: randomised, double blind, placebo controlled trial. BMJ 2011;342:d1980
   PubMedGoogle Scholar
• Ray CG, Kirschvink JF, Waxman SH, Kelley VC. Studies of anabolic steroids. Ii. The effect of oxandrolone on height and skeletal maturation in mongoloid children (a preliminary report). Am J Dis Child 1963;106:375-80
   Google Scholar
• Ray CG, Kirschvink JF, Waxman SH, Kelley VC. Studies of anabolic steroids. 3. The effect of oxandrolone on height and skeletal maturation in mongoloid children. Am J Dis Child 1965;110:618-23
   Google Scholar
• Zangeneh F, Steiner MM. Oxandrolone therapy in growth retardation of children. Am J Dis Child 1967;113:234-41
   Google Scholar
• Murphy KD, Thomas S, Mlcak RP, et al. Effects of long-term oxandrolone administration in severely burned children. Surgery 2004;136(2):219-24
   Google Scholar
• Przkora R, Jeschke MG, Barrow RE, et al. Metabolic and hormonal changes of severely burned children receiving long-term oxandrolone treatment. Ann Surg 2005;242(3):384-9
   PubMedGoogle Scholar
• Przkora R, Herndon DN, Suman OE. The effects of oxandrolone and exercise on muscle mass and function in children with severe burns. Pediatrics 2007;119:e109-1
   PubMed Web of Science ®Google Scholar
• Menke LA, Sas TC, de Muinck Keizer-Schrama SM, et al. Efficacy and safety of oxandrolone in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab 2010;95(3):1151-60
   PubMed Web of Science ®Google Scholar
• Zeger MP, Shah K, Kowal K, et al. Prospective study confirms oxandrolone-associated improvement in height in growth hormone-treated adolescent girls with Turner syndrome. Horm Res Paediatr 2011;75(1):38-46
   PubMed Web of Science ®Google Scholar
• Chagin AS, Vannesjo J, Savendahl L. Androgen receptor modulation does not affect longitudinal growth of cultured fetal rat metatarsal bones. Horm Res 2009;71(4):219-27
   Google Scholar
• Massarano AA, Brook CG, Hindmarsh PC, et al. Growth hormone secretion in Turner’s syndrome and influence of oxandrolone and ethinyl oestradiol. Arch Dis Child 1989;64(4):587-92
   Google Scholar
• Haeusler G, Schmitt K, Blumel P, et al. Insulin, insulin-like growth factor-binding protein-1, and sex hormone-binding globulin in patients with Turner’s syndrome: course over age in untreated patients and effect of therapy with growth hormone alone and in combination with oxandrolone. J Clin Endocrinol Metab 1996;81(2):536-41
   PubMedGoogle Scholar
• Bi LX, Wiren KM, Zhang XW, et al. The effect of oxandrolone treatment on human osteoblastic cells. J Burns Wounds 2007;6:e4
   Google Scholar
• Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24(1):153-61
   PubMed Web of Science ®Google Scholar
• Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010;69(5):872-5
   PubMed Web of Science ®Google Scholar
• Rossini M, Gatti D, Adami S. Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 2013;93(2):121-32
   Google Scholar
• Ng KW. Potential role of odanacatib in the treatment of osteoporosis. Clin Interv Aging 2012;7:235-47
   PubMed Web of Science ®Google Scholar
• McClung MR, Grauer A. Romosozumab in postmenopausal women with osteopenia. N Engl J Med 2014;370(17):1664-5
   PubMed Web of Science ®Google Scholar
• Lin C, Jiang X, Dai Z, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 2009;24(10):1651-61
   PubMed Web of Science ®Google Scholar
• Spatz J, Ellman R, Cloutier A, et al. Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J Bone Miner Res 2013;28(4):865-74
   PubMed Web of Science ®Google Scholar
• Schwarz P, Jørgensen NR, Abrahamsen B. Status of drug development for the prevention and treatment of osteoporosis. Expert Opin Drug Discov 2014;9(3):245-53
   PubMed Web of Science ®Google Scholar